Investor profile
LifeArc Ventures
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
LifeArc Ventures is the venture capital arm of LifeArc, a self-funded UK medical research charity. It invests in Seed to Series B therapeutics and medtech companies across all therapeutic areas and modalities, co-investing with other leading life sciences venture funds globally. As the firm states: "We invest collaboratively across the full spectrum of therapeutics and medtech companies which our investment team believes have the potential to deliver life-changing patient impact across a broad range of indications, while generating financial returns for LifeArc to reinvest in its core objectives." LifeArc Ventures offers portfolio companies a unique combination of venture funding, scientific support through LifeArc's labs in Stevenage and Edinburgh, and deep translational expertise. The fund focuses primarily on UK science but invests globally, and also runs a fund-of-funds strategy investing in leading global life sciences venture funds. Financial returns are returned to LifeArc to sustain its charitable mission of translating promising science into patient impact.
Notable quotes
“"This year we've announced four new investments, including our first in German, Swiss and Scandinavian" companies — geographic expansion as part of our long-term strategy to diversify the portfolio.”
“"Surgery Hero is an excellent example of how technology can be leveraged to enhance the experience for patients undergoing surgery and improve outcomes in a cost-effective way."”
“"Affect is easy to use, flexible, adapted to the needs of the individual, and backed by robust data-driven research."”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| GlycoEra AG | Series B | $130m | 2025-05-27 |
| Hillstar Bio | Series A | $67m | 2025-04-07 |
| Tribune Therapeutics | Series A | $25m | 2025-03-26 |
| Exciva GmbH | Series B | $56m | 2025-01-01 |
| Maxion Therapeutics | Series A | $72m | 2025-03-17 |
| Fluid Biomed Inc. | Series A | $27m | 2024-12-01 |
| AviadoBio | Series A | — | 2022-01-01 |
| Cytospire Therapeutics | Seed | — | 2023-01-01 |
| Affect Therapeutics | Series A | $16m | 2023-07-12 |
| Ikarovec | Seed | — | 2022-01-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Novo Holdings | 4 |
| Monograph Capital | 2 |
| BGF | 2 |
| ARTIS Ventures | 2 |
| Amplitude Ventures | 2 |
| Frazier Life Sciences | 2 |
Fit check
Is LifeArc Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit